|
EXEL | Exelixis, Inc. |
|
|
EXEL | Exelixis, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.20 |
| Leverage | 24.89% |
| Market Cap | $ 10.6B |
| PE | 16.75 |
| Dividend Yield | 0.00% |
| Profit | $ 633.6m |
| Margin | 28.06% |
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The company is headquartered in Alameda, California.